**Name of Journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO:** 18409

**Manuscript Type: TOPIC HIGHLIGHT**

**2015 Advances in Colorectal Cancer**

**Colorectal cancer: Metastases to a single organ**

Vatandoust S *et al*. Colorectal cancer: Single organ metastases

Sina Vatandoust, Timothy J Price, Christos S Karapetis

**Sina Vatandoust, Christos S Karapetis,** Department of Medical Oncology, Flinders Medical Centre, Adelaide, SA 5042, Australia

**Sina Vatandoust, Timothy J Price,** Flinders Centre for Innovation in Cancer, Flinders University, Adelaide, SA 5042, Australia

**Timothy J Price,** Department of Medical Oncology, The Queen Elizabeth Hospital, Adelaide, SA 5011, Australia

**Timothy J Price,** The University of Adelaide, Adelaide, SA 5000, Australia

**Author contributions:** All authors contributed to this work.

**Conflict-of-interest statement:** Authors declare no conflict of interests for this article.

**Open-Access:** This article is an open-access article which was selected byan in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to:**  **Sina Vatandoust, MD, FRACP,** Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Adelaide, SA, 5042, Australia. sina.vatandoust@health.sa.gov.au

**Telephone:** +61-8-82048997

**Fax:** +61-8-82044997

**Received:** April 19, 2015

**Peer-review started:** April 21, 2015

**First decision:** May 18, 2015

**Revised:** June 20, 2015

**Accepted:** August 29, 2015

**Article in press:**

**Published online:**

**Abstract**

Colorectal cancer (CRC) is a common malignancy worldwide. In CRC patients, metastases are the main cause of cancer-related mortality. In a group of metastatic CRC patients, the metastases are limited to a single site (solitary organ); the liver and lungs are the most commonly involved sites. When metastatic disease is limited to the liver and/or lungs, the resectability of the metastatic lesions will dictate the management approach and the outcome. Less commonly, the site of solitary organ CRC metastasis is the peritoneum. In these patients, cytoreduction followed by hyperthermic intraperitoneal chemotherapy may improve the outcome. Rarely, CRC involves other organs, such as the brain, bone, adrenals and spleen, as the only site of metastatic disease. There are limited data to guide clinical practice in these cases. Here, we have reviewed the disease characteristics, management approaches and prognosis based on the metastatic disease site in patients with CRC with metastases to a single organ.

**Key words:** Colorectal Cancer; Metastasis; Prognosis; Disease management; Liver metastasis; Lung metastasis; Brain metastasis; Bone metastasis; Peritoneal metastasis

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Colorectal cancer (CRC) is a common malignancy. In CRC patients, metastases are the main cause of cancer-related mortality. Cancer spread can sometimes be limited to a single organ, representing a malignancy with a distinct biological profile and clinical characteristics. In CRC patients with single site metastases, the resectability of the metastases and the site of metastatic disease affect the clinical characteristics, the optimal management approach and the prognosis.

Vatandoust S, Price TJ, Karapetis CS, Colorectal cancer: Metastases to a single organ. *World J Gastroenterol* 2015; In press

**INTRODUCTION**

Colorectal cancer (CRC) is one of the most common malignancies worldwide[[1](#_ENREF_1)] and continues to be one of the leading causes of cancer-related death globally[[2](#_ENREF_2)]. In CRC patients, similar to those with other malignancies, metastases are the main cause of cancer-related mortality. Distant metastatic disease has is present in approximately 25% of patients at initial diagnosis, and half of CRC patients will develop metastatic disease[[3](#_ENREF_3)]. Most patients with metastatic CRC have incurable disease. In this group of patients, median survival has improved from less than 10 mo with best supportive care to 14 mo with fluoropyrimidine treatment[[4](#_ENREF_4),[5](#_ENREF_5)] and to more than 2 years with a combination of various cytotoxic[[6](#_ENREF_6),[7](#_ENREF_7)] and biologic agents[[8](#_ENREF_8),[9](#_ENREF_9)].

The concept of oligometastatic cancer was first proposed two decades ago[[10](#_ENREF_10)]. Cancer spread can sometimes be limited to a single organ, representing a malignancy with a peculiar biological profile and clinical characteristics. In this group of patients, the prognosis differs significantly: some patients with resectable metastases can be offered potentially curative treatments, and occasionally, chemotherapy can be used to render the metastases resectable[[11](#_ENREF_11)], but the prognosis in others remains grim. Numerous factors are involved in this difference in prognosis. Here, we have reviewed the literature to clarify the prognosis of CRC patients with metastases to a single site (solitary organ) and the prognostic role of the metastatic disease site.

**LIVER**

The liver is the most common site of metastasis from CRC; this is thought to be due to the venous drainage of the colon and rectum. Approximately 50% of CRC patients will develop liver metastasis during the course of the disease[[12](#_ENREF_12)]. In patients with metastatic CRC, the liver is the sole organ with metastases in approximately one-third of patients[[13](#_ENREF_13)]. In a retrospective analysis of 780 patients with CRC and liver-only metastases (including both resectable and non-resectable cases), the median overall survival (mOS) was reported as 22.8 mo[[14](#_ENREF_14)]. Depending on the resectability of the metastases, patients with liver metastases from CRC have different prognoses.

**RESECTABLE LIVER METASTASIS**

Approximately 20% of patients with hepatic metastases present with resectable disease at diagnosis[[15](#_ENREF_15)]. According to one consensus statement, contraindications to resection include the following: unresectable extrahepatic disease, more than 70% liver involvement, liver failure, and being surgically unfit[[16](#_ENREF_16)]. Nevertheless, the selection criteria for hepatic resection are evolving and are beyond the scope of this review. In patients who undergo resection of liver metastases, a 5-year survival of 25% to 58%[[17-25](#_ENREF_17)] and a 10-year survival of 17% to 28%[[17](#_ENREF_17),[19-21](#_ENREF_19),[26](#_ENREF_26)] have been reported, and one study has reported a 20-year survival of 17%[[20](#_ENREF_20)] (Table 1). A systematic review of the published data showed a 5-year survival of approximately 30%, with the majority of these patients being disease-free[[27](#_ENREF_27)]. Studies have shown that a significant number of 5-year survivors progress to cancer-related death[[21](#_ENREF_21),[28](#_ENREF_28)]. However, it appears that patients who survive 10 years are cured[[21](#_ENREF_21),[29](#_ENREF_29)]. In patients with resectable liver metastases, perioperative chemotherapy with the FOLFOX regimen has been shown to improve progression-free survival[[30](#_ENREF_30)]. However, this approach has not been shown to improve overall survival[[31](#_ENREF_31)].

**NON-RESECTABLE LIVER METASTASIS**

The majority of patients with liver metastases from primary CRC have non-resectable disease[[32-35](#_ENREF_32)]. Historical data show that without treatment, these patients have a poor prognosis[[36](#_ENREF_36),[37](#_ENREF_37)]. Retrospective studies of this population suggest that the amount of liver replaced by the tumor is the most significant indicator of outcome[[38-42](#_ENREF_38)] (Table 2). In a large study by Stangl *et al*[39] that included 484 patients, 189 who did not have extrahepatic metastases had a median survival of 9.6 mo. In this group, patients with a lower volume of liver replaced by tumor and grade 1-2 (primary) disease with no extrahepatic and no mesenteric lymph node involvement had the highest median survival (21.3 mo; range, 5-68 mo; 95%CI: 15.6-34.1). According to these studies, the median survival of patients with CRC metastases confined to the liver with a low disease volume is in the range of 11 to 18 mo; with a higher disease volume, the range is 6 to 8 mo. These studies predate the currently available systemic treatments. Nevertheless, even with the improvements in the survival of patients with metastatic CRC using current chemotherapy regimens, patients with non-resectable liver metastases have a low 5-year survival rate[[43](#_ENREF_43)].

In some patients, hepatic metastases that are initially deemed non-resectable can be resected after neoadjuvant chemotherapy[[11](#_ENREF_11),[44](#_ENREF_44),[45](#_ENREF_45)]. Similar 5-year survival rates have been reported in this group compared to patients who initially had resectable disease[[46](#_ENREF_46)]. In some patients with non-resectable liver lesions, radiofrequency ablation is an option that may provide tumor control. In this group of patients, a median survival of 36-59 mo has been reported with local ablation[[47-50](#_ENREF_47)]. Selective intraoperative radiotherapy (SIRT) is another liver-directed treatment strategy that has been shown to control the progression of metastatic colon cancer within the liver. This involves injecting yttrium-labeled microspheres into the liver *via* the hepatic artery[[51](#_ENREF_51)]. Randomized phase III trials that evaluated the addition of SIRT to systemic chemotherapy as part of the treatment of metastatic CRC limited to the liver are underway[[52-54](#_ENREF_52)]. The SIRFLOX study results were presented in the recent Annual Meeting of American Society of Clinical Oncology. In this study addition of SIRT to standard chemotherapy did not improve overall progression free survival but improved liver progression free survival. Overall survival results from this study are not available yet[[55](#_ENREF_55)].

**LUNG**

The lungs are the second most common site of distant metastases from CRC[[56-58](#_ENREF_56)]. Previous studies have shown that 10-15% of patients with CRC develop lung metastases during the course of the disease[[59](#_ENREF_59),[60](#_ENREF_60)]. Compared to colon cancer, patients with rectal cancer are at a higher risk of synchronous and metachronous lung metastases[[58-60](#_ENREF_58)]. This is believed to be due to direct spread of rectal cancer into systemic circulation through the hemorrhoidal veins[[61](#_ENREF_61)]. Isolated lung metastases are thought to be less common: in two retrospective studies, 2.8%[[59](#_ENREF_59)] and 7.4%[[62](#_ENREF_62)] of patients were reported to have isolated lung metastases. In the multivariate analysis of 5654 CRC patients, those with isolated lung metastases seemed to have a significantly better prognosis compared to those who had another metastatic location in addition to the lungs[[59](#_ENREF_59)]. One retrospective study showed a significantly better prognosis for patients with lung-only disease compared to those with a single organ metastasis to another organ[[14](#_ENREF_14)].

**RESECTABLE LUNG METASTASIS**

In the absence of randomized prospective studies and based on data from retrospective series, it is widely accepted that surgery should be considered for the management of resectable pulmonary metastases from CRC[[63-65](#_ENREF_63)]. Based on the literature, the suitability criteria for the resection of pulmonary metastases include the following: control of the primary tumor; possible complete resection; and adequate pulmonary reserve to tolerate the planned resection[[66](#_ENREF_66)]. Various series have shown mOS of 36.2 mo to 49 mo, 5-year survival rates of 32% to 68%[[67-78](#_ENREF_67)] and 10-year survival rates of 11% to 34%[[76](#_ENREF_76),[79-81](#_ENREF_79)] in patients with CRC undergoing lung metastasectomy (Table 3).

A meta-analysis of the published data has suggested that in this group of patients, the absence of thoracic node involvement, prolonged disease-free interval (between primary tumor and metastatic spread), normal pre-thoracotomy carcinoembryonic antigen (CEA), and a single pulmonary lesion are associated with prolonged survival[[64](#_ENREF_64)]; of these criteria, the last three have also been shown to be of prognostic value in a separate analysis[[65](#_ENREF_65)].

**NON-RESECTABLE LUNG METASTASIS**

In the majority of patients with CRC and pulmonary involvement, the lung metastases are not resectable. In a prospective study of 70 patients with CRC and isolated unresectable lung metastases who were treated with chemotherapy[[82](#_ENREF_82)], the mOS was 19 mo (95%CI: 12.6-25.4 mo, range: 5-44 mo), with a 2-year OS rate of 38.8%. The first response assessment seemed to be a prognostic factor, with a mOS of 27 mo (95%CI: 23.4–30.6 mo) for patients with a partial response compared with 16 mo (95%CI: 8.3-23.7 mo) and 8 mo (95%CI: 5.2–10.8 mo) in patients with stable disease and disease progression, respectively (*P <* 0.01). Notably, the lung metastases in a small proportion of patients (5.7%) in this study became resectable with chemotherapy[[82](#_ENREF_82)]. In a retrospective study of patients with non-resected lung metastases who underwent palliative chemotherapy, Mitry *et al*[[59](#_ENREF_59)] reported 3-year survival rates of 14.4 and 15.3% for metachronous and synchronous lung metastases, respectively; the 5-year survival rates were reported to be 0 and 8.4%, respectively, for the same cohorts.

**PERITONEUM**

In retrospective studies of CRC patients, the rate of peritoneal metastases has been reported to be between 4% and 13%[[83-86](#_ENREF_83)], with the peritoneum as the only site of metastatic disease in approximately 4% of patients[[83](#_ENREF_83),[85](#_ENREF_85)]. The risk factors for peritoneal involvement include right-sided tumor, advanced T-stage, advanced N-stage, poor differentiation grade, mucinous adenocarcinoma and younger age at diagnosis[[87](#_ENREF_87)]. Historically, peritoneal carcinomatosis from CRC has been associated with poor prognosis with a median survival of 6-8 mo[[84](#_ENREF_84),[88](#_ENREF_88)]. Intraperitoneal chemotherapy has been suggested to improve outcomes in these patients. In a retrospective analysis of 523 patients with CRC and peritoneal involvement as the sole metastatic site who underwent cytoreductive surgery and intraperitoneal chemotherapy, the overall 1-year, 3-year, and 5-year survival rates were 81%, 41%, and 27%, respectively. In that study, the median survival was 30.1 mo[[89](#_ENREF_89)].

A randomized trial by Verwaal *et al*[[90](#_ENREF_90)] showed that in patients with peritoneal metastases of CRC or positive cytology of ascites, in the absence of other distant metastases, cytoreduction followed by hyperthermic intraperitoneal chemotherapy (HIPEC) offers a statistically significant advantage in terms of survival (median disease-specific survival of 22.2 mo in the HIPEC arm versus 12.6 mo in the standard arm) and progression-free survival (12.6 mo in the HIPEC arm versus 7.7 mo in the standard arm). Importantly, in the standard arm of this study, patients received chemotherapy with fluorouracil and leucovorin. In a case-control study, including 48 cases in each arm, patients with resectable peritoneal metastases had a median survival of 24 mo with systemic chemotherapy; in the cytoreduction plus HIPEC group, the median survival reached 62.7 mo, with a 5-year survival rate of 51%[[91](#_ENREF_91)]. In another study of 67 cases and 38 controls, the mOS was significantly prolonged in the HIPEC group (34.7 mo *vs* 16.8 mo, *P <* 0.001)[[92](#_ENREF_92)]. In both of the latter studies, both arms received modern systemic chemotherapy regimens[[91](#_ENREF_91),[92](#_ENREF_92)]. This is especially important because in patients with colorectal peritoneal carcinomatosis, modern systemic therapies might be associated with improved outcome (in patients treated systemically alone or with cytoreductive surgery combined with perioperative intraperitoneal chemotherapy)[[93](#_ENREF_93)].

It appears that in patients with peritoneal metastases from CRC, cytoreductive surgery and intraperitoneal chemotherapy may improve the outcomes, but there is still insufficient evidence in this area[[94](#_ENREF_94)].

Single organ metastases from CRC are less common in other sites, and below we have reviewed some of these scenarios.

**BRAIN**

Compared to liver and lung metastases, cerebral metastases from CRC are uncommon. The incidence of brain metastases in patients with CRC has been reported to be between 0.3% and 6% in different series[[95-98](#_ENREF_95)]. The incidence might be increasing with the recent developments in the treatment of CRC[[99](#_ENREF_99)]. In patients with brain metastases due to CRC, the primary tumor is more frequently located in the distal colon and rectum rather than in the proximal colon[[100](#_ENREF_100),[101](#_ENREF_101)]. Brain metastases usually occur later in the course of the disease, and most patients already have metastases in other organs, especially the liver and lung, by the time the brain metastases are diagnosed. The prognosis remains dismal, and the median survival of patients with brain metastases from CRC has been reported to be between 3 and 6 mo[[100](#_ENREF_100),[102-105](#_ENREF_102)], which seems to be worse than the median survival of patients with brain metastasis due to other malignancies[[103](#_ENREF_103)]. In 2%-10% of patients with brain metastasis from CRC, the brain is the only site of metastatic disease[[100](#_ENREF_100),[106](#_ENREF_106),[107](#_ENREF_107)]. In these patients, prognostic factors include age, performance status and a controlled primary tumor[[108](#_ENREF_108)].

The management approach in patients with brain metastases from solid tumors (including CRC) depends on multiple factors, including the following: patient’s performance status, the status of the primary cancer, number/location of the brain lesions, and the presence of leptomeningeal disease[[109](#_ENREF_109)]. Local treatments for brain metastases include surgery, whole brain radiotherapy (WBRT) and stereotactic radiosurgery[[110](#_ENREF_110)]. Aggressive local treatments (surgical or radiosurgery in addition to WBRT) improve the outcomes in patients with a good performance status and a limited number of brain metastases[[111](#_ENREF_111),[112](#_ENREF_112)]. Retrospective studies have shown that in selected patients with brain metastases from CRC, the mOS may improve (up to 12-15 mo) with aggressive local treatment of the brain lesions[[101](#_ENREF_101),[102](#_ENREF_102),[107](#_ENREF_107),[113-117](#_ENREF_113)].

**BONE**

The incidence of bone metastasis from CRC has been reported to be 10.7% to 23.7% in an autopsy series, with signet-ring cell pathology showing a high incidence of bony metastases[[118](#_ENREF_118)]. One retrospective study using bone scans and plain radiography showed that the incidence of skeletal metastasis in patients with CRC was 6.6%; in this study, 83.9% of the patients had other organ metastases, and 16.9% were deemed to have bony metastases only[[119](#_ENREF_119)]. One study used positron emission tomography and/or CT scans in 252 patients with a diagnosis of CRC and found the incidence of bone metastasis to be 5.5%, with a median time from diagnosis to the detection of bone metastasis of 21 mo; in this study, none of the patients had bone-only metastatic disease[[120](#_ENREF_120)]. Different series have shown that the median survival of patients with bone metastases is between 5 to 7 mo after detecting the bone metastases[[121](#_ENREF_121),[122](#_ENREF_122)]. There are only a few case reports of patients with solitary bone metastasis from CRC, with a wide range of prognoses[[123-130](#_ENREF_123)]. In some of these cases, the use of radiotherapy[[124](#_ENREF_124)] or surgical resection[[129](#_ENREF_129),[130](#_ENREF_130)] of the bone metastases has been reported to achieve favorable results.

**OTHER ORGANS**

There are only a few case reports of CRC with isolated metastases to the adrenal glands[[131-133](#_ENREF_131)] and the spleen[[134](#_ENREF_134)]. Surgical resection of the metastatic lesion may play a role in such cases.

**DISCUSSION**

In patients with CRC and single-site metastatic disease, the site of the metastatic disease affects both the treatment approach and the prognosis. In patients with oligometastatic disease limited to the liver and/or the lung (and maybe the peritoneum), the most essential factor that affects the prognosis is the resectability of the metastatic lesion(s). Favorable prognosis in these patients with resectable disease might be due to several factors: in general, such patients have a lower metastatic burden and are in the earlier phases of the disease compared with CRC patients with unresectable metastases, and their performance status is also generally better as they are well enough to tolerate an operation. These confounding factors make it difficult to attribute the improved survival to only one variable; nonetheless, it is likely that the favorable biology of the primary disease plays a role in this complex picture.

In patients with non-resectable oligometastatic disease, those with metastatic disease to the liver or lung have a better prognosis than those with metastases to the peritoneum, brain or bone[[14](#_ENREF_14)]. The relationship between patterns of metastases from tumors and different prognoses can be explained by the “seed and soil” hypothesis, which was first formulated by Paget[[135](#_ENREF_135)]. According to this hypothesis, the cancer cells (the seed) must find a suitable microenvironment in the target organ (the soil) for the metastasis to occur. Metastasis is a highly complex process that requires adaptations in the cancer cells as well as cross-talk between the cancer cells and the microenvironment both in the primary tumor as well as in the target organ[[136-138](#_ENREF_136)]. Previous studies have shown that the involvement of specific organs depends on cancer cell gene expression[[139-141](#_ENREF_139)]. It is conceivable that such differences in the metastasizing cancer cells not only lead to the involvement of various organs but also have an impact on the outcome of the disease. Other factors may also affect the prognosis of patients with different metastatic sites. One is the effect of the target organ on the cancer cells. Studies have shown that cancer cell gene expression, behavior and response to treatment are affected by the target organ microenvironment[[142-145](#_ENREF_142)].

In patients with metastatic cancer, including patients with single-site metastatic disease, there are several other factors that may also affect survival, including the involvement of vital organs, which plays an important role in the case of brain metastases. The metastatic burden and the disease volume are also important. In conclusion, in patients with CRC and single-site metastasis, the resectability of the metastases and the metastatic disease site affect the clinical characteristics, the optimal management approach and the prognosis.

**REFERENCES**

1 **Jemal A**, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011; **61**: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]

2 **Jemal A**, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. *Cancer Epidemiol Biomarkers Prev* 2010; **19**: 1893-1907 [PMID: 20647400 DOI: 10.1158/1055-9965.EPI-10-0437]

3 **Van Cutsem E**, Oliveira J. Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol* 2009; **20 Suppl 4**: 61-63 [PMID: 19454465 DOI: 10.1093/annonc/mdp130]

4 **de Gramont A**, Bosset JF, Milan C, Rougier P, Bouché O, Etienne PL, Morvan F, Louvet C, Guillot T, François E, Bedenne L. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. *J Clin Oncol* 1997; **15**: 808-815 [PMID: 9053508]

5 **Van Cutsem E**, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA, Marshall JL, Mitchell EP, Perez-Manga G, Rougier P, Schmiegel W, Schoelmerich J, Sobrero A, Schilsky RL. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. *Br J Cancer* 2004; **90**: 1190-1197 [PMID: 15026800 DOI: 10.1038/sj.bjc.6601676]

6 **Grothey A**, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. *J Clin Oncol* 2004; **22**: 1209-1214 [PMID: 15051767 DOI: 10.1200/JCO.2004.11.037]

7 **Tournigand C**, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. *J Clin Oncol* 2004; **22**: 229-237 [PMID: 14657227 DOI: 10.1200/JCO.2004.05.113]

8 **Hurwitz H**, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* 2004; **350**: 2335-2342 [PMID: 15175435 DOI: 10.1056/NEJMoa032691]

9 **Van Cutsem E**, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. *J Clin Oncol* 2011; **29**: 2011-2019 [PMID: 21502544 DOI: 10.1200/JCO.2010.33.5091]

10 **Hellman S**, Weichselbaum RR. Oligometastases. *J Clin Oncol* 1995; **13**: 8-10 [PMID: 7799047]

11 **Leonard GD**, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. *J Clin Oncol* 2005; **23**: 2038-2048 [PMID: 15774795 DOI: 10.1200/JCO.2005.00.349]

12 **Biasco G**, Derenzini E, Grazi G, Ercolani G, Ravaioli M, Pantaleo MA, Brandi G. Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. *Cancer Treat Rev* 2006; **32**: 214-228 [PMID: 16546323 DOI: 10.1016/j.ctrv.2005.12.011]

13 **Jönsson K**, Gröndahl G, Salö M, Tingstedt B, Andersson R. Repeated Liver Resection for Colorectal Liver Metastases: A Comparison with Primary Liver Resections concerning Perioperative and Long-Term Outcome. *Gastroenterol Res Pract* 2012; **2012**: 568214 [PMID: 22973305 DOI: 10.1155/2012/568214]

14 **Khattak MA**, Martin HL, Beeke C, Price T, Carruthers S, Kim S, Padbury R, Karapetis CS. Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer. *Clin Colorectal Cancer* 2012; **11**: 247-254 [PMID: 22763194 DOI: 10.1016/j.clcc.2012.06.004]

15 **Sheth KR**, Clary BM. Management of hepatic metastases from colorectal cancer. *Clin Colon Rectal Surg* 2005; **18**: 215-223 [PMID: 20011304 DOI: 10.1055/s-2005-916282]

16 **Poston GJ**, Adam R, Alberts S, Curley S, Figueras J, Haller D, Kunstlinger F, Mentha G, Nordlinger B, Patt Y, Primrose J, Roh M, Rougier P, Ruers T, Schmoll HJ, Valls C, Vauthey NJ, Cornelis M, Kahan JP. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. *J Clin Oncol* 2005; **23**: 7125-7134 [PMID: 16192596 DOI: 10.1200/JCO.2005.08.722]

17 **Choti MA**, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL. Trends in long-term survival following liver resection for hepatic colorectal metastases. *Ann Surg* 2002; **235**: 759-766 [PMID: 12035031 DOI: 10.1097/00000658-200206000-00002]

18 **Nordlinger B**, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, Jaeck D. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. *Cancer* 1996; **77**: 1254-1262 [PMID: 8608500 DOI: 10.1002/(SICI)1097-0142(19960401)77:7<1254::AID-CNCR5>3.0.CO;2-I ]

19 **Rees M**, Tekkis PP, Welsh FK, O'Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. *Ann Surg* 2008; **247**: 125-135 [PMID: 18156932 DOI: 10.1097/SLA.0b013e31815aa2c2]

20 **Scheele J**, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. *World J Surg* 1995; **19**: 59-71 [PMID: 7740812 DOI: 10.1007/BF00316981]

21 **Tomlinson JS**, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D'Angelica M. Actual 10-year survival after resection of colorectal liver metastases defines cure. *J Clin Oncol* 2007; **25**: 4575-4580 [PMID: 17925551 DOI: 10.1200/JCO.2007.11.0833]

22 **Fong Y**, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. *Ann Surg* 1999; **230**: 309-18; discussion 318-21 [PMID: 10493478 DOI: 10.1097/00000658-199909000-00004]

23 **Abdalla EK**, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. *Ann Surg* 2004; **239**: 818-25; discussion 825-7 [PMID: 15166961]

24 **Fernandez FG**, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). *Ann Surg* 2004; **240**: 438-47; discussion 447-50 [PMID: 15319715 DOI: 10.1097/01.sla.0000138076.72547.b1]

25 **Jamison RL**, Donohue JH, Nagorney DM, Rosen CB, Harmsen WS, Ilstrup DM. Hepatic resection for metastatic colorectal cancer results in cure for some patients. *Arch Surg* 1997; **132**: 505-10; discussion 511 [PMID: 9161393 DOI: 10.1001/archsurg.1997.01430290051008]

26 **Wei AC**, Greig PD, Grant D, Taylor B, Langer B, Gallinger S. Survival after hepatic resection for colorectal metastases: a 10-year experience. *Ann Surg Oncol* 2006; **13**: 668-676 [PMID: 16523369 DOI: 10.1245/ASO.2006.05.039]

27 **Simmonds PC**, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. *Br J Cancer* 2006; **94**: 982-999 [PMID: 16538219 DOI: 10.1038/sj.bjc.6603033]

28 **Viganò L**, Ferrero A, Lo Tesoriere R, Capussotti L. Liver surgery for colorectal metastases: results after 10 years of follow-up. Long-term survivors, late recurrences, and prognostic role of morbidity. *Ann Surg Oncol* 2008; **15**: 2458-2464 [PMID: 18463927 DOI: 10.1245/s10434-008-9935-9]

29 **Pulitanò C**, Castillo F, Aldrighetti L, Bodingbauer M, Parks RW, Ferla G, Wigmore SJ, Garden OJ. What defines 'cure' after liver resection for colorectal metastases? Results after 10 years of follow-up. *HPB (Oxford)* 2010; **12**: 244-249 [PMID: 20590894 DOI: 10.1111/j.1477-2574.2010.00155.x]

30 **Nordlinger B**, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. *Lancet* 2008; **371**: 1007-1016 [PMID: 18358928 DOI: 10.1016/S0140-6736(08)60455-9]

31 **Nordlinger B**, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van Cutsem E, Scheithauer W, Gruenberger T. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. *Lancet Oncol* 2013; **14**: 1208-1215 [PMID: 24120480 DOI: 10.1016/S1470-2045(13)70447-9]

32 **Alberts SR**, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. *J Clin Oncol* 2005; **23**: 9243-9249 [PMID: 16230673 DOI: 10.1200/JCO.2005.07.740]

33 **Kemeny N**. Management of liver metastases from colorectal cancer. *Oncology (Williston Park)* 2006; **20**: 1161-176, 1179; discussion 1161-176, 1161-176, [PMID: 17024869]

34 **Konopke R**, Roth J, Volk A, Pistorius S, Folprecht G, Zöphel K, Schuetze C, Laniado M, Saeger HD, Kersting S. Colorectal liver metastases: an update on palliative treatment options. *J Gastrointestin Liver Dis* 2012; **21**: 83-91 [PMID: 22457864]

35 **Muratore A**, Zorzi D, Bouzari H, Amisano M, Massucco P, Sperti E, Capussotti L. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? *Ann Surg Oncol* 2007; **14**: 766-770 [PMID: 17103261 DOI: 10.1245/s10434-006-9146-1]

36 **Bengmark S**, Hafström L. The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. *Cancer* 1969; **23**: 198-202 [PMID: 5763253 DOI: 10.1002/1097-0142(196901)23:1<198::AID-CNCR2820230126>3.0.CO;2-J]

37 **PESTANA C**, REITEMEIER RJ, MOERTEL CG, JUDD ES, DOCKERTY MB. THE NATURAL HISTORY OF CARCINOMA OF THE COLON AND RECTUM. *Am J Surg* 1964; **108**: 826-829 [PMID: 14233766 DOI: 10.1016/0002-9610(64)90041-8]

38 **Chang AE**, Steinberg SM, Culnane M, White DE. Determinants of survival in patients with unresectable colorectal liver metastases. *J Surg Oncol* 1989; **40**: 245-251 [PMID: 2927137 DOI: 10.1002/jso.2930400409]

39 **Stangl R**, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. *Lancet* 1994; **343**: 1405-1410 [PMID: 7515134 DOI: 10.1016/S0140-6736(94)92529-1]

40 **Arnaud JP**, Dumont P, Adloff M, Leguillou A, Py JM. Natural history of colorectal carcinoma with untreated liver metastases. *Surg Gastroenterol* 1984; **3**: 37-42 [PMID: 6522907]

41 **Yamamura T**, Tsukikawa S, Akaishi O, Tanaka K, Matsuoka H, Hanai A, Oikawa H, Ozasa T, Kikuchi K, Matsuzaki H, Yamaguchi S. Multivariate analysis of the prognostic factors of patients with unresectable synchronous liver metastases from colorectal cancer. *Dis Colon Rectum* 1997; **40**: 1425-1429 [PMID: 9407979 DOI: 10.1007/BF02070706]

42 **Johnson WR**, McDermott FT, Pihl E, Milne BJ, Price AB, Hughes ES. Palliative operative management in rectal carcinoma. *Dis Colon Rectum* 1981; **24**: 606-609 [PMID: 6172244 DOI: 10.1007/BF02605756]

43 **Adam R**, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghémard O, Levi F, Bismuth H. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. *Ann Surg* 2004; **240**: 644-57; discussion 657-8 [PMID: 15383792 DOI: 10.1097/01.sla.0000141198.92114.f6]

44 **Giacchetti S**, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, Brienza S, Alafaci E, Bertheault-Cvitkovic F, Jasmin C, Reynes M, Bismuth H, Misset JL, Lévi F. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. *Ann Oncol* 1999; **10**: 663-669 [PMID: 10442188 DOI: 10.1023/A:1008347829017]

45 **Pozzo C**, Basso M, Cassano A, Quirino M, Schinzari G, Trigila N, Vellone M, Giuliante F, Nuzzo G, Barone C. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. *Ann Oncol* 2004; **15**: 933-939 [PMID: 15151951 DOI: 10.1093/annonc/mdh217]

46 **Bismuth H**, Adam R, Lévi F, Farabos C, Waechter F, Castaing D, Majno P, Engerran L. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. *Ann Surg* 1996; **224**: 509-20; discussion 520-2 [PMID: 8857855]

47 **Berber E**, Tsinberg M, Tellioglu G, Simpfendorfer CH, Siperstein AE. Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis. *J Gastrointest Surg* 2008; **12**: 1967-1972 [PMID: 18688683 DOI: 10.1007/s11605-008-0622-8]

48 **Gillams AR**, Lees WR. Five-year survival following radiofrequency ablation of small, solitary, hepatic colorectal metastases. *J Vasc Interv Radiol* 2008; **19**: 712-717 [PMID: 18440460 DOI: 10.1016/j.jvir.2008.01.016]

49 **Oshowo A**, Gillams A, Harrison E, Lees WR, Taylor I. Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. *Br J Surg* 2003; **90**: 1240-1243 [PMID: 14515293 DOI: 10.1002/bjs.4264]

50 **Solbiati L**, Livraghi T, Goldberg SN, Ierace T, Meloni F, Dellanoce M, Cova L, Halpern EF, Gazelle GS. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. *Radiology* 2001; **221**: 159-166 [PMID: 11568334 DOI: 10.1148/radiol.2211001624]

51 **Stubbs RS**, Cannan RJ, Mitchell AW. Selective internal radiation therapy with 90yttrium microspheres for extensive colorectal liver metastases. *J Gastrointest Surg* 2001; **5**: 294-302 [PMID: 11360053 DOI: 10.1016/S1091-255X(01)80051-2]

52 **Gibbs P**, Gebski V, Van Buskirk M, Thurston K, Cade DN, Van Hazel GA; SIRFLOX Study Group. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study. *BMC Cancer* 2014; **14**: 897 [PMID: 25487708 DOI: 10.1186/1471-2407-14-897]

53 FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer (FOXFIREGlobal) [ClinicalTrials.gov identifier: NCT01721954]

54 Comparing HAI-90Y (SIR-spheres) Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer [ClinicalTrials.gov identifier: NCT01895257]

55 **Gibbs P**, Gebski V, Van Buskirk M, Thurston K, Cade DN, Van Hazel GA; SIRFLOX Study Group. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study. *BMC Cancer* 2014; **14**: 897 [DOI: 10.1186/1471-2407-14-897]

56 **Galandiuk S**, Wieand HS, Moertel CG, Cha SS, Fitzgibbons RJ, Pemberton JH, Wolff BG. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. *Surg Gynecol Obstet* 1992; **174**: 27-32 [PMID: 1729745]

57 **Weiss L**, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder M, Fenoglio-Preiser CM, Napier J, Horne CH, Lopez MJ. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. *J Pathol* 1986; **150**: 195-203 [PMID: 3806280 DOI: 10.1002/path.1711500308]

58 **Kobayashi H**, Mochizuki H, Sugihara K, Morita T, Kotake K, Teramoto T, Kameoka S, Saito Y, Takahashi K, Hase K, Oya M, Maeda K, Hirai T, Kameyama M, Shirouzu K, Muto T. Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study. *Surgery* 2007; **141**: 67-75 [PMID: 17188169 DOI: 10.1016/j.surg.2006.07.020]

59 **Mitry E**, Guiu B, Cosconea S, Jooste V, Faivre J, Bouvier AM. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. *Gut* 2010; **59**: 1383-1388 [PMID: 20732912 DOI: 10.1136/gut.2010.211557]

60 **Pihl E**, Hughes ES, McDermott FT, Johnson WR, Katrivessis H. Lung recurrence after curative surgery for colorectal cancer. *Dis Colon Rectum* 1987; **30**: 417-419 [PMID: 3595358 DOI: 10.1007/BF02556487]

61 **HUGHES ES**, CUTHBERTSON AM. Recurrence after curative excision of carcinoma of the large bowel. *JAMA* 1962; **182**: 1303-1306 [PMID: 13955552 DOI: 10.1001/jama.1962.03050520001001]

62 **Tan KK**, Lopes Gde L, Sim R. How uncommon are isolated lung metastases in colorectal cancer? A review from database of 754 patients over 4 years. *J Gastrointest Surg* 2009; **13**: 642-648 [PMID: 19082673 DOI: 10.1007/s11605-008-0757-7]

63 **Gonzalez M**, Ris HB, Krueger T, Gervaz P. Colorectal cancer and thoracic surgeons: close encounters of the third kind. *Expert Rev Anticancer Ther* 2012; **12**: 495-503 [PMID: 22500686 DOI: 10.1586/era.12.21]

64 **Gonzalez M**, Poncet A, Combescure C, Robert J, Ris HB, Gervaz P. Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. *Ann Surg Oncol* 2013; **20**: 572-579 [PMID: 23104709 DOI: 10.1245/s10434-012-2726-3]

65 **Salah S**, Watanabe K, Welter S, Park JS, Park JW, Zabaleta J, Ardissone F, Kim J, Riquet M, Nojiri K, Gisabella M, Kim SY, Tanaka K, Al-Haj Ali B. Colorectal cancer pulmonary oligometastases: pooled analysis and construction of a clinical lung metastasectomy prognostic model. *Ann Oncol* 2012; **23**: 2649-2655 [PMID: 22547539 DOI: 10.1093/annonc/mds100]

66 **Warwick R**, Page R. Resection of pulmonary metastases from colorectal carcinoma. *Eur J Surg Oncol* 2007; **33 Suppl 2**: S59-S63 [PMID: 18023132 DOI: 10.1016/j.ejso.2007.09.018]

67 **Borasio P**, Gisabella M, Billé A, Righi L, Longo M, Tampellini M, Ardissone F. Role of surgical resection in colorectal lung metastases: analysis of 137 patients. *Int J Colorectal Dis* 2011; **26**: 183-190 [PMID: 20960207 DOI: 10.1007/s00384-010-1075-6]

68 **Hwang MR**, Park JW, Kim DY, Chang HJ, Kim SY, Choi HS, Kim MS, Zo JI, Oh JH. Early intrapulmonary recurrence after pulmonary metastasectomy related to colorectal cancer. *Ann Thorac Surg* 2010; **90**: 398-404 [PMID: 20667318 DOI: 10.1016/j.athoracsur.2010.04.058]

69 **Riquet M**, Foucault C, Cazes A, Mitry E, Dujon A, Le Pimpec Barthes F, Médioni J, Rougier P. Pulmonary resection for metastases of colorectal adenocarcinoma. *Ann Thorac Surg* 2010; **89**: 375-380 [PMID: 20103301 DOI: 10.1016/j.athoracsur.2009.10.005]

70 **Watanabe K**, Nagai K, Kobayashi A, Sugito M, Saito N. Factors influencing survival after complete resection of pulmonary metastases from colorectal cancer. *Br J Surg* 2009; **96**: 1058-1065 [PMID: 19672932 DOI: 10.1002/bjs.6682]

71 **Welter S**, Jacobs J, Krbek T, Poettgen C, Stamatis G. Prognostic impact of lymph node involvement in pulmonary metastases from colorectal cancer. *Eur J Cardiothorac Surg* 2007; **31**: 167-172 [PMID: 17150367 DOI: 10.1016/j.ejcts.2006.11.004]

72 **Yedibela S**, Klein P, Feuchter K, Hoffmann M, Meyer T, Papadopoulos T, Göhl J, Hohenberger W. Surgical management of pulmonary metastases from colorectal cancer in 153 patients. *Ann Surg Oncol* 2006; **13**: 1538-1544 [PMID: 17009154 DOI: 10.1245/s10434-006-9100-2]

73 **Inoue M**, Ohta M, Iuchi K, Matsumura A, Ideguchi K, Yasumitsu T, Nakagawa K, Fukuhara K, Maeda H, Takeda S, Minami M, Ohno Y, Matsuda H. Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma. *Ann Thorac Surg* 2004; **78**: 238-244 [PMID: 15223436 DOI: 10.1016/j.athoracsur.2004.02.017]

74 **Kanemitsu Y**, Kato T, Hirai T, Yasui K. Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer. *Br J Surg* 2004; **91**: 112-120 [PMID: 14716804 DOI: 10.1002/bjs.4370]

75 **Pfannschmidt J**, Muley T, Hoffmann H, Dienemann H. Prognostic factors and survival after complete resection of pulmonary metastases from colorectal carcinoma: experiences in 167 patients. *J Thorac Cardiovasc Surg* 2003; **126**: 732-739 [PMID: 14502146 DOI: 10.1016/S0022-5223(03)00587-7]

76 **Saito Y**, Omiya H, Kohno K, Kobayashi T, Itoi K, Teramachi M, Sasaki M, Suzuki H, Takao H, Nakade M. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment. *J Thorac Cardiovasc Surg* 2002; **124**: 1007-1013 [PMID: 12407386 DOI: 10.1067/mtc.2002.125165]

77 **Zink S**, Kayser G, Gabius HJ, Kayser K. Survival, disease-free interval, and associated tumor features in patients with colon/rectal carcinomas and their resected intra-pulmonary metastases. *Eur J Cardiothorac Surg* 2001; **19**: 908-913 [PMID: 11404151 DOI: 10.1016/S1010-7940(01)00724-2]

78 **Moore KH**, McCaughan BC. Surgical resection for pulmonary metastases from colorectal cancer. *ANZ J Surg* 2001; **71**: 143-146 [PMID: 11277142 DOI: 10.1046/j.1440-1622.2001.02057.x]

79 **McCormack PM**, Burt ME, Bains MS, Martini N, Rusch VW, Ginsberg RJ. Lung resection for colorectal metastases. 10-year results. *Arch Surg* 1992; **127**: 1403-1406 [PMID: 1365684 DOI: 10.1001/archsurg.1992.01420120037006]

80 **Okumura S**, Kondo H, Tsuboi M, Nakayama H, Asamura H, Tsuchiya R, Naruke T. Pulmonary resection for metastatic colorectal cancer: experiences with 159 patients. *J Thorac Cardiovasc Surg* 1996; **112**: 867-874 [PMID: 8873711 DOI: 10.1016/S0022-5223(96)70085-5]

81 **Rama N**, Monteiro A, Bernardo JE, Eugénio L, Antunes MJ. Lung metastases from colorectal cancer: surgical resection and prognostic factors. *Eur J Cardiothorac Surg* 2009; **35**: 444-449 [PMID: 19136273 DOI: 10.1016/j.ejcts.2008.10.047]

82 **Li WH**, Peng JJ, Xiang JQ, Chen W, Cai SJ, Zhang W. Oncological outcome of unresectable lung metastases without extrapulmonary metastases in colorectal cancer. *World J Gastroenterol* 2010; **16**: 3318-3324 [PMID: 20614489 DOI: 10.3748/wjg.v16.i26.3318]

83 **Jayne DG**, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. *Br J Surg* 2002; **89**: 1545-1550 [PMID: 12445064 DOI: 10.1046/j.1365-2168.2002.02274.x]

84 **Lemmens VE**, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JW, de Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. *Int J Cancer* 2011; **128**: 2717-2725 [PMID: 20715167 DOI: 10.1002/ijc.25596]

85 **Segelman J**, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. *Br J Surg* 2012; **99**: 699-705 [PMID: 22287157 DOI: 10.1002/bjs.8679]

86 **Koppe MJ**, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. *Ann Surg* 2006; **243**: 212-222 [PMID: 16432354 DOI: 10.1097/01.sla.0000197702.46394.16]

87 **Klaver YL**, Lemmens VE, Nienhuijs SW, Luyer MD, de Hingh IH. Peritoneal carcinomatosis of colorectal origin: Incidence, prognosis and treatment options. *World J Gastroenterol* 2012; **18**: 5489-5494 [PMID: 23112540 DOI: 10.3748/wjg.v18.i39.5489]

88 **Chu DZ**, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. *Cancer* 1989; **63**: 364-367 [PMID: 2910444 DOI: 10.1002/1097-0142(19890115)63:2<364::AID-CNCR2820630228>3.0.CO;2-V]

89 **Elias D**, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dubè P, Glehen O. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. *J Clin Oncol* 2010; **28**: 63-68 [PMID: 19917863 DOI: 10.1200/JCO.2009.23.9285]

90 **Verwaal VJ**, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. *Ann Surg Oncol* 2008; **15**: 2426-2432 [PMID: 18521686 DOI: 10.1245/s10434-008-9966-2]

91 **Elias D**, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, Ferron G, Guilloit JM, Meeus P, Goéré D, Bonastre J. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. *J Clin Oncol* 2009; **27**: 681-685 [PMID: 19103728 DOI: 10.1200/JCO.2008.19.7160]

92 **Franko J**, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. *Cancer* 2010; **116**: 3756-3762 [PMID: 20564081 DOI: 10.1002/cncr.25116]

93 **Chua TC**, Morris DL, Saxena A, Esquivel J, Liauw W, Doerfer J, Germer CT, Kerscher AG, Pelz JO. Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study. *Ann Surg Oncol* 2011; **18**: 1560-1567 [PMID: 21203904 DOI: 10.1245/s10434-010-1522-1]

94 **Coccolini F**, Gheza F, Lotti M, Virzì S, Iusco D, Ghermandi C, Melotti R, Baiocchi G, Giulini SM, Ansaloni L, Catena F. Peritoneal carcinomatosis. *World J Gastroenterol* 2013; **19**: 6979-6994 [PMID: 24222942 DOI: 10.3748/wjg.v19.i41.6979]

95 **Barnholtz-Sloan JS**, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. *J Clin Oncol* 2004; **22**: 2865-2872 [PMID: 15254054 DOI: 10.1200/JCO.2004.12.149]

96 **Cascino TL**, Leavengood JM, Kemeny N, Posner JB. Brain metastases from colon cancer. *J Neurooncol* 1983; **1**: 203-209 [PMID: 6678969 DOI: 10.1007/BF00165604]

97 **Rovirosa A**, Bodi R, Vicente P, Alastuey I, Giralt J, Salvador L. [Cerebral metastases in adenocarcinoma of the colon]. *Rev Esp Enferm Dig* 1991; **79**: 281-283 [PMID: 2054216]

98 **Schouten LJ**, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. *Cancer* 2002; **94**: 2698-2705 [PMID: 12173339 DOI: 10.1002/cncr.10541]

99 **Tabouret E**, Chinot O, Metellus P, Tallet A, Viens P, Gonçalves A. Recent trends in epidemiology of brain metastases: an overview. *Anticancer Res* 2012; **32**: 4655-4662 [PMID: 23155227]

100 **Damiens K**, Ayoub JP, Lemieux B, Aubin F, Saliba W, Campeau MP, Tehfe M. Clinical features and course of brain metastases in colorectal cancer: an experience from a single institution. *Curr Oncol* 2012; **19**: 254-258 [PMID: 23144573 DOI: 10.3747/co.19.1048]

101 **Hammoud MA**, McCutcheon IE, Elsouki R, Schoppa D, Patt YZ. Colorectal carcinoma and brain metastasis: distribution, treatment, and survival. *Ann Surg Oncol* 1996; **3**: 453-463 [PMID: 8876887 DOI: 10.1007/BF02305763]

102 **Farnell GF**, Buckner JC, Cascino TL, O'Connell MJ, Schomberg PJ, Suman V. Brain metastases from colorectal carcinoma. The long term survivors. *Cancer* 1996; **78**: 711-716 [PMID: 8756361 DOI: 10.1002/(SICI)1097-0142(19960815)78: 4<711: : AID-CNCR3>3.0.CO; 2-H]

103 **Kruser TJ**, Chao ST, Elson P, Barnett GH, Vogelbaum MA, Angelov L, Weil RJ, Pelley R, Suh JH. Multidisciplinary management of colorectal brain metastases: a retrospective study. *Cancer* 2008; **113**: 158-165 [PMID: 18459179 DOI: 10.1002/cncr.23531]

104 **Amichetti M**, Lay G, Dessì M, Orrù S, Farigu R, Orrù P, Farci D, Melis S. Results of whole brain radiation therapy in patients with brain metastases from colorectal carcinoma. *Tumori* 2005; **91**: 163-167 [PMID: 15948545]

105 **Schoeggl A**, Kitz K, Reddy M, Zauner C. Stereotactic radiosurgery for brain metastases from colorectal cancer. *Int J Colorectal Dis* 2002; **17**: 150-155 [PMID: 12049308 DOI: 10.1007/s00384-001-0362-7]

106 **Alden TD**, Gianino JW, Saclarides TJ. Brain metastases from colorectal cancer. *Dis Colon Rectum* 1996; **39**: 541-545 [PMID: 8620805 DOI: 10.1007/BF02058708]

107 **Kye BH**, Kim HJ, Kang WK, Cho HM, Hong YK, Oh ST. Brain metastases from colorectal cancer: the role of surgical resection in selected patients. *Colorectal Dis* 2012; **14**: e378-e385 [PMID: 22288509 DOI: 10.1111/j.1463-1318.2012.02962.x]

108 **Gaspar L**, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. *Int J Radiat Oncol Biol Phys* 1997; **37**: 745-751 [PMID: 9128946 DOI: 10.1016/S0360-3016(96)00619-0]

109 **Vogelbaum MA**, Suh JH. Resectable brain metastases. *J Clin Oncol* 2006; **24**: 1289-1294 [PMID: 16525184 DOI: 10.1200/JCO.2005.04.6235.]

110 **Ba JL**, Jandial R, Nesbit A, Badie B, Chen M. Current and emerging treatments for brain metastases. *Oncology (Williston Park)* 2015; **29**: 250-257 [PMID: 25952487 DOI: 10.1200/JCO.2005.04.6235]

111 **Kalkanis SN**, Kondziolka D, Gaspar LE, Burri SH, Asher AL, Cobbs CS, Ammirati M, Robinson PD, Andrews DW, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell RA, Ryken TC, Linskey ME. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. *J Neurooncol* 2010; **96**: 33-43 [PMID: 19960230 DOI: 10.1007/s11060-009-0061-8]

112 **Owonikoko TK**, Arbiser J, Zelnak A, Shu HK, Shim H, Robin AM, Kalkanis SN, Whitsett TG, Salhia B, Tran NL, Ryken T, Moore MK, Egan KM, Olson JJ. Current approaches to the treatment of metastatic brain tumours. *Nat Rev Clin Oncol* 2014; **11**: 203-222 [PMID: 24569448 DOI: 10.1038/nrclinonc.2014.25]

113 **Wroński M**, Arbit E. Resection of brain metastases from colorectal carcinoma in 73 patients. *Cancer* 1999; **85**: 1677-1685 [PMID: 10223560 DOI: 10.1002/(SICI)1097-0142(19990415)85:8<1677::AID-CNCR6>3.0.CO;2-C]

114 **Noura S**, Ohue M, Shingai T, Fujiwara A, Imada S, Sueda T, Yamada T, Fujiwara Y, Ohigashi H, Yano M, Ishikawa O. Brain metastasis from colorectal cancer: prognostic factors and survival. *J Surg Oncol* 2012; **106**: 144-148 [PMID: 22287384 DOI: 10.1002/jso.23055]

115 **Mege D**, Ouaissi M, Fuks D, Metellus P, Peltier J, Dufour H, Regimbeau JM, Dahan L, Sielezneff I, Sastre B. Patients with brain metastases from colorectal cancer are not condemned. *Anticancer Res* 2013; **33**: 5645-5648 [PMID: 24324111]

116 **Suzuki Y**, Yamaguchi T, Matsumoto H, Nakano D, Honda G, Shinoura N, Karasawa K, Takahashi K. Prognostic factors and treatment effects in patients with curatively resected brain metastasis from colorectal cancer. *Dis Colon Rectum* 2014; **57**: 56-63 [PMID: 24316946 DOI: 10.1097/01.dcr.0000436998.30504.98]

117 **Aprile G**, Zanon E, Tuniz F, Iaiza E, De Pauli F, Pella N, Pizzolitto S, Buffoli A, Piga A, Skrap M, Fasola G. Neurosurgical management and postoperative whole-brain radiotherapy for colorectal cancer patients with symptomatic brain metastases. *J Cancer Res Clin Oncol* 2009; **135**: 451-457 [PMID: 18779977 DOI: 10.1007/s00432-008-0468-1]

118 **Katoh M**, Unakami M, Hara M, Fukuchi S. Bone metastasis from colorectal cancer in autopsy cases. *J Gastroenterol* 1995; **30**: 615-618 [PMID: 8574333 DOI: 10.1007/BF02367787]

119 **Kanthan R**, Loewy J, Kanthan SC. Skeletal metastases in colorectal carcinomas: a Saskatchewan profile. *Dis Colon Rectum* 1999; **42**: 1592-1597 [PMID: 10613479 DOI: 10.1007/BF02236213]

120 **Roth ES**, Fetzer DT, Barron BJ, Joseph UA, Gayed IW, Wan DQ. Does colon cancer ever metastasize to bone first? a temporal analysis of colorectal cancer progression. *BMC Cancer* 2009; **9**: 274 [PMID: 19664211 DOI: 10.1186/1471-2407-9-274]

121 **Nozue M**, Oshiro Y, Kurata M, Seino K, Koike N, Kawamoto T, Taniguchi H, Todoroki T, Fukao K. Treatment and prognosis in colorectal cancer patients with bone metastasis. *Oncol Rep* 2002; **9**: 109-112 [PMID: 11748466 DOI: 10.3892/or.9.1.109]

122 **Santini D**, Tampellini M, Vincenzi B, Ibrahim T, Ortega C, Virzi V, Silvestris N, Berardi R, Masini C, Calipari N, Ottaviani D, Catalano V, Badalamenti G, Giannicola R, Fabbri F, Venditti O, Fratto ME, Mazzara C, Latiano TP, Bertolini F, Petrelli F, Ottone A, Caroti C, Salvatore L, Falcone A, Giordani P, Addeo R, Aglietta M, Cascinu S, Barni S, Maiello E, Tonini G. Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. *Ann Oncol* 2012; **23**: 2072-2077 [PMID: 22219016 DOI: 10.1093/annonc/mdr572]

123 **Anoop TM**, George S, Divya KP, Jabbar PK. Metastatic phalangeal osteolysis as an initial presentation of carcinoma colon. *Am J Surg* 2010; **200**: e61-e63 [PMID: 20870210 DOI: 10.1016/j.amjsurg.2010.02.016]

124 . Management of a Solitary Bone Metastasis to the Tibia from Colorectal Cancer. *Case Rep Gastroenterol* 2009; **3**: 354-359 [PMID: 21103253 DOI: 10.1159/000239626]

125 **Gamblin TC**, Santos RS, Baratz M, Landreneau RJ. Metastatic colon cancer to the hand. *Am Surg* 2006; **72**: 98-100 [PMID: 16494196]

126 **Kose F**, Sakalli H, Sezer A, Mertsoylu H, Pourbagher A, Reyhan M, Ozyilkan O. Colon adenocarcinoma and solitary tibia metastasis: rare entity. *J Gastrointest Cancer* 2008; **39**: 146-148 [PMID: 19241183 DOI: 10.1007/s12029-009-9055-1]

127 **Sheen AJ**, Drake D, Langton S, Sherlock DJ. Unusual bony colorectal metastases in post-hepatometastasectomy patients. *J Hepatobiliary Pancreat Surg* 2002; **9**: 379-382 [PMID: 12353151 DOI: 10.1007/s005340200044]

128 **Eddekkaoui H**, Chekrine T, Sahraoui S, Marouane S, Alj A, Zamiati S, Nechad M, Benider A. [Isolated bone metastasis of the radius metachronous of colorectal cancer]. *Pan Afr Med J* 2013; **14**: 161 [PMID: 23819003 DOI: 10.11604/pamj.2013.14.161.1938]

129 **Onesti JK**, Mascarenhas CR, Chung MH, Davis AT. Isolated metastasis of colon cancer to the scapula: is surgical resection warranted? *World J Surg Oncol* 2011; **9**: 137 [PMID: 22029634 DOI: 10.1186/1477-7819-9-137]

130 **Choi SJ**, Kim JH, Lee MR, Lee CH, Kuh JH, Kim JR. Long-term disease-free survival after surgical resection for multiple bone metastases from rectal cancer. *World J Clin Oncol* 2011; **2**: 326-328 [PMID: 21876853 DOI: 10.5306/wjco.v2.i8.326]

131 **Cantarini R**, Covotta F, Aucello A, Montalto G, Procacciante F, Marcheggiani A, Covotta A. Surgical treatment of isolated lung and adrenal metastasis from colorectal cancer. Case report. *Ann Ital Chir* 2012; **83**: 337-342 [PMID: 22759471]

132 **Castaldi P**, Biondi A, Rausei S, Persiani R, Mirk P, Rufini V. An unusual case of adrenal metastasis from colorectal cancer: computed tomography and fluorine 18-fluoro-deoxy-glucose positron emission tomography-computed tomography features and literature review. *Case Rep Oncol* 2010; **3**: 416-422 [PMID: 21532984 DOI: 10.1159/000322508]

133 **Kosmidis C**, Efthimiadis C, Anthimidis G, Levva S, Ioannidou G, Zaramboukas T, Emmanouilides C, Baka S, Kosmidou M, Basdanis G, Fachantidis E. Adrenalectomy for solitary adrenal metastasis from colorectal cancer: A case report. *Cases J* 2008; **1**: 49 [PMID: 18638404 DOI: 10.1186/1757-1626-1-49]

134 **Abi Saad GS**, Hussein M, El-Saghir NS, Termos S, Sharara AI, Shamseddine A. Isolated splenic metastasis from colorectal cancer. *Int J Clin Oncol* 2011; **16**: 306-313 [PMID: 21258837 DOI: 10.1007/s10147-010-0182-2]

135 **Paget S**. The distribution of secondary growths in cancer of the breast. 1889. *Cancer Metastasis Rev* 1989; **8**: 98-101 [PMID: 2673568]

136 **Talmadge JE**, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. *Cancer Res* 2010; **70**: 5649-5669 [PMID: 20610625 DOI: 10.1158/0008-5472.CAN-10-1040]

137 **Hanahan D**, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011; **144**: 646-674 [PMID: 21376230 DOI: 10.1016/j.cell.2011.02.013]

138 **Schlüter K**, Gassmann P, Enns A, Korb T, Hemping-Bovenkerk A, Hölzen J, Haier J. Organ-specific metastatic tumor cell adhesion and extravasation of colon carcinoma cells with different metastatic potential. *Am J Pathol* 2006; **169**: 1064-1073 [PMID: 16936278 DOI: 10.2353/ajpath.2006.050566]

139 **Kang Y**, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA, Massagué J. A multigenic program mediating breast cancer metastasis to bone. *Cancer Cell* 2003; **3**: 537-549 [PMID: 12842083 DOI: 10.1016/S1535-6108(03)00132-6]

140 **Minn AJ**, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massagué J. Genes that mediate breast cancer metastasis to lung. *Nature* 2005; **436**: 518-524 [PMID: 16049480 DOI: 10.1038/nature03799]

141 **Zang YW**, Gu XD, Xiang JB, Chen ZY. Brain metastases from colorectal cancer: microenvironment and molecular mechanisms. *Int J Mol Sci* 2012; **13**: 15784-15800 [PMID: 23443093 DOI: 10.3390/ijms131215784]

142 **Nakajima M**, Morikawa K, Fabra A, Bucana CD, Fidler IJ. Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells. *J Natl Cancer Inst* 1990; **82**: 1890-1898 [PMID: 2174463 DOI: 10.1093/jnci/82.24.1890]

143 **Fidler IJ**, Wilmanns C, Staroselsky A, Radinsky R, Dong Z, Fan D. Modulation of tumor cell response to chemotherapy by the organ environment. *Cancer Metastasis Rev* 1994; **13**: 209-222 [PMID: 7923551 DOI: 10.1007/BF00689637]

144 **Dalton WS**. The tumor microenvironment as a determinant of drug response and resistance. *Drug Resist Updat* 1999; **2**: 285-288 [PMID: 11504502 DOI: 10.1054/drup.1999.0097]

145 **Tarin D**. Erratum to: Clinical and Biological Implications of the Tumor Microenvironment. *Cancer Microenviron* 2012; **5**: 113 [DOI: 10.1007/s12307-012-0112-0]

**P-Reviewer:** Akar E **S-Editor:** Yu J **L-Editor:** **E-Editor:**

**Table 1 Hepatic metastasectomy: Large retrospective studies**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **First author/year** | **Patients, *n*** | **Median overall survival (mo)** | **5-year survival** | **10-year survival** | **20-year survival** |
| Rees[[19](#_ENREF_19)]/2008  | 929 |  | 36% | 23% |  |
| Choti[[17](#_ENREF_17)]/2002  | 226 | 46  | 40% | 26% |  |
| Fong[[22](#_ENREF_22)]/1999 | 1001 | 42  | 37% | 22% |  |
| Nordlinger[[18](#_ENREF_18)]/1996  | 1568 |  | 28% |  |  |
| Scheele[[20](#_ENREF_20)]/1995  | 434 | 40  | 33% | 20% | 17% |

**Table 2 Retrospective studies of patients with unresected liver metastases**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Patients without extrahepatic metastases, *n*** | **The extent of liver involvement** | **Median overall survival (mo)** | **Treatments** |
| Ymamura *et al*[[41](#_ENREF_41)], 1997(*n* = 73)  | 67 | Metastases in one lobe | 13 | Chemotherapy(chemotherapy did not significantly affect survival in multivariate analysis) |
| Less than four metastases inboth lobes | 12 |
| More than five metastases inboth lobes | 6 |
| Stangl *et al*[[39](#_ENREF_39)], 1994  | 189 | ≤ 25% | 11.1 | No treatment |
| > 25% | 6.3 |
| Chang *et al*[[38](#_ENREF_38)], 1989 (*n* = 67) | 49 |  | 15.1 | Floxuridine (hepatic arterial or intravenously) |
| < 25% | 23.8 |
| 25%-75% | 14.8 |
| > 75% | 7.3 |
| Arnaud*et al*[[40](#_ENREF_40)], 1984 (*n* = 56) | (not specified) | One lobe | 17 | NA |
| Both lobes | 8.23 |
| Johnson*et al*[[42](#_ENREF_42)], 1981 | 51 | Solitary liver Metastasis (*n* = 12) | 18 | NA |
| Multiple metastases in one lobe (*n* = 6) | 7 |
| Multiple metastases in both lobes (*n* = 33) | 8 |

mOS: Median overall survival; NA: Not available.

**Table 3 Retrospective studies including ≥ 100 patients with resectable lung metastases from colorectal cancer**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **First author** | **Year** | ***n*** | **median survival (mo)** | **5-year survival rate (%)** |
| Borasio[[67](#_ENREF_67)] | 2011 | 137 | 36.2 | 55 |
| Hwang[[68](#_ENREF_68)] | 2010 | 125 | 37 | 48 |
| Riquet[[69](#_ENREF_69)] | 2010 | 127 | 45 | 41 |
| Watanabe[[70](#_ENREF_70)] | 2009 | 113 | NA | 68 |
| Welter[[71](#_ENREF_71)] | 2007 | 169 | 47.2 | 39 |
| Yedibela[[72](#_ENREF_72)] | 2006 | 153 | 43 | 37 |
| Inoue[[73](#_ENREF_73)] | 2004 | 128 | 49 | 45 |
| Kanemitsu[[74](#_ENREF_74)] | 2004 | 313 | 38 | 38 |
| Pfannschmidt[[75](#_ENREF_75)] | 2003 | 167 | 40 | 32 |
| Saito[[76](#_ENREF_76)] | 2002 | 165 | NA | 40 |
| Zink[[77](#_ENREF_77)] | 2001 | 110 | 41 | 32 |

NA: Not available.